MNX1-AS1 is a Functional Oncogene That Induces EMT and Activates the AKT/mTOR Pathway and MNX1 in Breast Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Jan 31

PMID 30697072

Citations 23

Authors

Yue Cheng

Yiqi Pan

Yiyuan Pan

Ouchen Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: lncRNAs have recently been identified as key regulators of basic biological processes as well as the pathogenesis of various diseases. Previous studies have shown that lncRNA MNX1-AS1 promotes cell migration and invasion in ovarian cancer; however, its role in regulating breast cancer-associated biological processes remains unclear.

Materials And Methods: We obtained paired specimens of breast cancer tissues and adjacent normal tissues by modified radical mastectomy from 36 patients, in addition to four breast cancer cell lines (MDA-MB-231, MDA-MB-468, BT-549 and MCF-7). RNA was isolated from these tissues and cell lines and subsequently subjected to quantitative real-time polymerase chain reaction. This was followed by bisulfite deep sequencing. The cells were also transfected with siRNA against MNX1-AS1. The cells were then subject to cell proliferation, Transwell migration and invasion assays. Finally, Western blotting analysis was conducted to determine expression levels of MNX1, 5-cadherin, Snail and Slug.

Results: Our results show that MNX1-AS1 expression was significantly higher in breast cancer tissues than adjacent normal tissues. Moreover, knockdown/overexpression of MNX1-AS1 inhibits/promotes proliferation, migration and invasion of breast cancer cells. MNX1-AS1 and its natural sense transcript MNX1 are expressed synergistically in breast tumor tissues. Our results suggest that MNX1-AS1 is a functional oncogene that induces epithelial-mesenchymal transition, in addition to activating AKT/mTOR pathway and its natural sense transcript MNX1 in breast cancer cells.

Conclusion: Our data indicate that MNX1-AS1 can serve as a novel therapeutic target in breast cancer.

Citing Articles

Molecular landscape of congenital vertebral malformations: recent discoveries and future directions.

Szoszkiewicz A, Bukowska-Olech E, Jamsheer A Orphanet J Rare Dis. 2024; 19(1):32.

PMID: 38291488 PMC: 10829358. DOI: 10.1186/s13023-024-03040-0.

PI3K/Akt signalling pathway-associated long noncoding RNA signature predicts the prognosis of laryngeal cancer patients.

Nie Q, Cao H, Yang J, Liu T, Wang B Sci Rep. 2023; 13(1):14764.

PMID: 37679508 PMC: 10485045. DOI: 10.1038/s41598-023-41927-3.

Metformin and long non-coding RNAs in breast cancer.

Gholami M, Klashami Z, Ebrahimi P, Mahboobipour A, Farid A, Vahidi A J Transl Med. 2023; 21(1):155.

PMID: 36849958 PMC: 9969691. DOI: 10.1186/s12967-023-03909-x.

MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation.

Wu Y, Wang Y, Yao H, Li H, Meng F, Li Q J Exp Clin Cancer Res. 2022; 41(1):337.

PMID: 36476366 PMC: 9727912. DOI: 10.1186/s13046-022-02547-3.

LncRNA MNX1-AS1 contributes to lung adenocarcinoma progression by targeting the miR-34a/SIRT1 axis.

Liu G, Zhang Y, Zhang X, Liu Y, Xu Y, Cui S Am J Transl Res. 2022; 14(7):4977-4989.

PMID: 35958481 PMC: 9360842.

References

Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N . mTOR, translation initiation and cancer. Oncogene. 2006; 25(48):6416-22. DOI: 10.1038/sj.onc.1209888. View

Franke T . PI3K/Akt: getting it right matters. Oncogene. 2008; 27(50):6473-88. DOI: 10.1038/onc.2008.313. View

Laplante M, Sabatini D . mTOR signaling at a glance. J Cell Sci. 2009; 122(Pt 20):3589-94. PMC: 2758797. DOI: 10.1242/jcs.051011. View

Zoncu R, Efeyan A, Sabatini D . mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2010; 12(1):21-35. PMC: 3390257. DOI: 10.1038/nrm3025. View

Yecies J, Manning B . mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl). 2011; 89(3):221-8. DOI: 10.1007/s00109-011-0726-6. View

Musgrove E, Caldon C, Barraclough J, Stone A, Sutherland R . Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011; 11(8):558-72. DOI: 10.1038/nrc3090. View

Cicenas J, Valius M . The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011; 137(10):1409-18. DOI: 10.1007/s00432-011-1039-4. View

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

Puisieux A, Brabletz T, Caramel J . Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014; 16(6):488-94. DOI: 10.1038/ncb2976. View

10.

Xing Z, Park P, Lin C, Yang L . LncRNA BCAR4 wires up signaling transduction in breast cancer. RNA Biol. 2015; 12(7):681-9. PMC: 4615247. DOI: 10.1080/15476286.2015.1053687. View

11.

Shuvalov O, Petukhov A, Daks A, Fedorova O, Ermakov A, Melino G . Current genome editing tools in gene therapy: new approaches to treat cancer. Curr Gene Ther. 2015; 15(5):511-29. DOI: 10.2174/1566523215666150818110241. View

12.

Schmitt A, Chang H . Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016; 29(4):452-463. PMC: 4831138. DOI: 10.1016/j.ccell.2016.03.010. View

13.

Ke H, Zhao L, Feng X, Xu H, Zou L, Yang Q . NEAT1 is Required for Survival of Breast Cancer Cells Through FUS and miR-548. Gene Regul Syst Bio. 2016; 10(Suppl 1):11-7. PMC: 4849421. DOI: 10.4137/GRSB.S29414. View

14.

Nieto M, Huang R, Jackson R, Thiery J . EMT: 2016. Cell. 2016; 166(1):21-45. DOI: 10.1016/j.cell.2016.06.028. View

15.

Zhang L, Wang J, Wang Y, Zhang Y, Castro P, Shao L . MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer. Cancer Res. 2016; 76(21):6290-6298. PMC: 5093064. DOI: 10.1158/0008-5472.CAN-16-0087. View

16.

Chaffer C, San Juan B, Lim E, Weinberg R . EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016; 35(4):645-654. DOI: 10.1007/s10555-016-9648-7. View

17.

Zhao X, Ren G . LncRNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation by Inhibiting MicroRNA-9 in MCF-7 Cells. J Breast Cancer. 2017; 19(4):349-357. PMC: 5204041. DOI: 10.4048/jbc.2016.19.4.349. View

18.

Das M . MNX1: a novel prostate cancer oncogene. Lancet Oncol. 2017; 17(12):e521. DOI: 10.1016/S1470-2045(16)30553-8. View

19.

Goyal A, Myacheva K, Gross M, Klingenberg M, Duran Arque B, Diederichs S . Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res. 2017; 45(3):e12. PMC: 5388423. DOI: 10.1093/nar/gkw883. View

20.

Schmitt A, Chang H . Long Noncoding RNAs: At the Intersection of Cancer and Chromatin Biology. Cold Spring Harb Perspect Med. 2017; 7(7). PMC: 5495049. DOI: 10.1101/cshperspect.a026492. View